{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-326969","form_type":"8-K","ticker":"SRPT","cik":"0000873303","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2025-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.418023+00:00","generated_at":"2026-05-16T12:40:59.208847+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sarepta exchanges $291.4M of 1.25% notes for 4.875% notes due 2030 plus $31.6M cash","bullets":["Exchanged ~$291.4M of existing 1.25% Convertible Senior Notes due 2027 for new 4.875% Convertible Notes due 2030 plus ~$31.6M cash.","New notes issued as additional notes under August 2025 indenture; total 4.875% notes now ~$893.4M outstanding.","Exchange involved holders including entity affiliated with board member Michael Chambers.","Transaction closed December 18, 2025; extends maturity from 2027 to 2030 at higher coupon."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-326969","json":"https://secwatch.observer/filing/0001193125-25-326969.json","markdown":"https://secwatch.observer/filing/0001193125-25-326969.md","text":"https://secwatch.observer/filing/0001193125-25-326969.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/873303/000119312525326969/0001193125-25-326969-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/873303/000119312525326969/d32354d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:40:59.208847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"439382dbb2f6a5c5498f69360a86074a0d0a62d3","claim":"Sarepta Therapeutics, Inc. incurred convertible notes of approximately $291.4 million with certain holders (including Michael A. Chambers Living Trust) at 4.875% maturing due 2030.","evidence_excerpt":"the holders party thereto agreed to exchange with the Company approximately $291.4 million in aggregate principal amount of Existing Convertible Notes held by them for consideration consisting of (i) approximately $291.4 million in aggregate principal amount of 4.875% Convertible Senior Notes due 2030 (the “New Convertible Notes”) and (ii) an aggregate of approximately $31.6 million in cash.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/873303/000119312525326969/0001193125-25-326969-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"approximately $291.4 million"},{"label":"Counterparty","value":"certain holders (including Michael A. Chambers Living Trust)"},{"label":"Rate","value":"4.875%"},{"label":"Maturity","value":"due 2030"},{"label":"Event","value":"incurrence"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}